- Home
- RYOJ vs CVM Comparison
RYOJ vs CVM Comparison
Compare RYOJ & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYOJ | CVM |
|---|---|---|
| Founded | 2015 | 1983 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 32.4M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | RYOJ | CVM |
|---|---|---|
| Price | $2.27 | $3.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.4K | ★ 42.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $1.81 | $0.18 |
| 52 Week High | $11.43 | $13.48 |
Technical Indicators
Market Signals| Indicator | RYOJ | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 36.29 | 37.95 |
| Support Level | $1.84 | $2.02 |
| Resistance Level | $2.39 | $6.71 |
| Average True Range (ATR) | 0.24 | 0.41 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 10.00 | 27.72 |
Price Performance
Historical ComparisonAbout RYOJ rYojbaba Co. Ltd.
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.